Please Wait.....
Report
New Zealand Insulin Drugs and Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029
Market Report I 2024-02-17 I 70 Pages I Mordor Intelligence
The New Zealand Insulin Drugs and Devices Market size is estimated at USD 523.18 million in 2024, and is expected to reach USD 552.60 million by 2029, growing at a CAGR of 1.10% during the forecast period (2024-2029).
After COVID-19 was detected, the risk of developing type 1 diabetes increased. The largest risk was in young pediatric and older adult patients with COVID-19. Type 1 diabetic patients were more likely to become infected with the virus and suffer from potentially fatal complications such as diabetic ketoacidosis. It was vital that patients had access to diabetic services and received high-quality clinical treatment, which included diabetes screening, education, and monitoring of complications and control.
To control blood sugar levels, the hormone insulin stimulates the liver, muscle, and fat cells to absorb glucose from the blood. It makes it easier for cells to absorb glucose for cellular energy use. Type 1 diabetes develops when the pancreas cannot produce enough insulin to meet the body's requirements.
Diabetes is typically regarded as a disease connected to lifestyle. The prevalence of the disease has dramatically increased over time due to the rising global population. All those with Type 1 diabetes and between 10% and 25% of those with Type 2 diabetes, totaling around 100 million individuals worldwide, require insulin. More than half of the people in New Zealand who need insulin today still do not have access to it or can afford it, even though insulin has been used to treat diabetes for more than 90 years. Insulin Patients with type-1 diabetes need drugs and delivery systems since their bodies cannot make insulin independently; those with type-2 diabetes also need insulin, especially if they are having trouble controlling their diabetes with oral meds.
New Zealand Insulin Drugs & Devices Market Trends
Rising diabetes prevalence
Type-1 diabetes has an unknown specific origin, whereas type-2 diabetes is brought on by daily lifestyle decisions and adjustments. Compared to ten years ago, the prevalence rate of type-2 diabetes has quadrupled. Over the past 20 years, type 1 diabetes mellitus (T1DM) has become much more common. This rise in frequency is largely attributable to the rise in obesity, which is the main risk factor for T1DM. Diabetes is one of the chronic diseases with the fastest growth rate in the US. One of the top three nations with a high incidence of diabetes in India. Based on lifestyle choices, numerous reports and surveys have shown a sharp rise in the population of people with diabetes.
Healthcare services in New Zealand are frequently separated into "primary care" and "secondary care." Most people often attend primary care as their first source of care. Typically, this is your family doctor or general practitioner. Although patients are required to pay for this service, those with low incomes frequently qualify for a discounted cost. In New Zealand, all children under the age of six can see a doctor without paying a fee. GP visits typically cost between NZ 45 and NZ 55, depending on the physician. There is no extra fee for visitors from other nations for a GP visit. After seeing their physician, patients may be referred to secondary care, typically considered specialized treatment. Specialist diabetes, specialist eye, specialist renal, and hospital services are just a few examples of the services typically managed out of the major hospitals. Patients can request a referral to specialized diabetic services if they are having any issues with their diabetes or, in some cases, if they use insulin for their diabetes. Although the expert services are free, some diabetes doctors also have private practices.
Insulin Drugs segment Expected to Witness Highest Growth Rate Over the Forecast Period
The Insulin Drugs are expected to grow with a CAGR of more than 4% in the market during the forecast period.
The Ministry of Health helped the New Zealand Society for the Study of Diabetes (NZSSD) release type 2 diabetes management guidelines recently, and they state that while the Special Authority criteria for empagliflozin and dulaglutide ensure access for those at high risk of cardiovascular and renal disease, the funding restriction is not entirely consistent with best practice. Public hospital departments offer free treatment for any complications or problems associated with diabetes. Except for New Zealand, the available therapeutic alternatives are comparable to those in every other developed country.
The types of diabetes medications sold in New Zealand are regulated by a government agency called Pharmac. As a result, New Zealand cannot access several pharmaceuticals that are supplied elsewhere. Nevertheless, there is frequently a medicine on the market that is almost identical. You can get insulin and practically all diabetes treatments in New Zealand. Novo Nordisk and Eli Lilly, the leading insulin producers, each has a wide range of goods available in New Zealand. Two widely available very short-acting insulin analogs are Novo Nordisk NovoRapid and Eli Lilly Humalog. Medication costs are the same throughout New Zealand. In New Zealand, each prescription medication will set you back USD 5.00. The roll-out of many new products, increasing international research collaborations in technology advancement, and increasing awareness about diabetes among people are expected to boost the market.
New Zealand Insulin Drugs & Devices Industry Overview
The New Zealand Insulin Drugs and Devices Market is moderately consolidated with few significant and generic players. The major players are working on innovations in insulin drugs and devices which is evident from the companies spending on research and developments to strengthen their market presence.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.3 Market Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Insulin Drugs (Value and Volume, 2017 - 2028)
5.1.1 Basal or Long Acting Insulins
5.1.1.1 Lantus (Insulin Glargine)
5.1.1.2 Levemir (Insulin Detemir)
5.1.1.3 Toujeo (Insulin Glargine)
5.1.1.4 Tresiba (Insulin Degludec)
5.1.1.5 Basaglar (Insulin Glargine)
5.1.2 Bolus or Fast Acting Insulins
5.1.2.1 NovoRapid/Novolog (Insulin Aspart)
5.1.2.2 Humalog (Insulin Lispro)
5.1.2.3 Apidra (Insulin Glulisine)
5.1.3 Traditional Human Insulins
5.1.3.1 Novolin/Actrapid/Insulatard
5.1.3.2 Humulin
5.1.3.3 Insuman
5.1.4 Biosimilar Insulins
5.1.4.1 Insulin Glargine Biosimilars
5.1.4.2 Human Insulin Biosimilars
5.2 Combination drugs (Value and Volume, 2017 - 2028)
5.2.1 Insulin combinations
5.2.1.1 NovoMix (Biphasic Insulin Aspart)
5.2.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
5.2.1.3 Xultophy (Insulin Degludec and Liraglutide)
5.2.2 Oral Combinations
5.2.2.1 Janumet (Sitagliptin and Metformin)
5.3 Non-Insulin Injectable drugs (Value and Volume, 2017 - 2028)
5.3.1 GLP-1 receptor agonists
5.3.1.1 Victoza (Liraglutide)
5.3.1.2 Byetta (Exenatide)
5.3.1.3 Bydureon (Exenatide)
5.3.1.4 Trulicity (Dulaglutide)
5.3.1.5 Lyxumia (Lixisenatide)
5.3.2 Amylin Analogue
5.3.2.1 Symlin (Pramlintide)
5.4 Insulin Device (Value and Volume, 2017 - 2028)
5.4.1 Insulin Pumps
5.4.1.1 Insulin Pump Devices
5.4.1.2 Insulin Pump Reservoirs
5.4.1.3 Insulin Infusion sets
5.4.2 Insulin Pens
5.4.2.1 Cartridges in reusable pens
5.4.2.2 Disposable insulin pens
5.4.3 Insulin Syringes
5.4.4 Insulin Jet Injectors
6 MARKET INDICATORS
6.1 Type-1 Diabetic Population (2017 - 2028)
6.2 Type-2 Diabetic Population (2017 - 2028)
7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Takeda
7.1.2 Novo Nordisk
7.1.3 Pfizer
7.1.4 Eli Lilly
7.1.5 Janssen Pharmaceuticals
7.1.6 Astellas
7.1.7 Boehringer Ingelheim
7.1.8 Merck And Co.
7.1.9 AstraZeneca
7.1.10 Bristol Myers Squibb
7.1.11 Novartis
7.1.12 Sanofi
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security